CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 20 hours ago

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.

Zacks Investment Research • Jul 24, 2026

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therapeutics for a couple of the firm's funds. While it's typically considered a gene-editing play (and even named after the underlying genomic science), that's not all this biotechnology outfit is working on.

The Motley Fool • Jul 22, 2026

Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead

CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.

Seeking Alpha • Jul 21, 2026

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Zacks Investment Research • Jul 20, 2026

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.

Zacks Investment Research • Jul 17, 2026

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.

Zacks Investment Research • Jul 16, 2026

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Jul 14, 2026

3 Reasons to Buy CRISPR Therapeutics Stock

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.

The Motley Fool • Jul 10, 2026

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.

Zacks Investment Research • Jul 10, 2026